Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cervical Ripening Drugs Market: By Drug Type, By Route of Administration, By Distribution Channel, and Geography
Cervical Ripening Drugs Market: By Drug Type, By Route of Administration, By Distribution Channel, and Geography
Cervical Ripeningsize Drugs Market size was valued at US$ X million in 2023 and is poised to grow at a significant CAGR of X% over 2024-2030. The softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. Cervical ripening drugs market is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix.
The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins. Growing usage of cervical ripening drugs before the induction of labor, rise in R&D activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
x %Largest Market
North AmericaFastest Growing Market
Asia Pacific
Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in the market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.
Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
x % |
|
By Drug Type |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The key segments covered in the cervical ripening drugs market are technology, components, application, and end-users.
Increase In Livestock Feed Production
The Cervical ripening drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1.Executive Summary |
| 2.Global Cervical Ripening Drugs Market Introduction |
| 2.1.Global Cervical Ripening Drugs Market - Taxonomy |
| 2.2.Global Cervical Ripening Drugs Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Route Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Cervical Ripening Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cervical Ripening Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cervical Ripening Drugs Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Prostaglandins |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Oxytocin |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Progesterone Receptor Antagonists |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Relaxin |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Estrogen |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Cervical Ripening Drugs Market By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intravenous |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Vaginal |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Cervical Ripening Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Cervical Ripening Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Cervical Ripening Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Prostaglandins |
| 9.1.2.Oxytocin |
| 9.1.3.Progesterone Receptor Antagonists |
| 9.1.4.Relaxin |
| 9.1.5.Estrogen |
| 9.1.6.Others |
| 9.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Intravenous |
| 9.2.3.Vaginal |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Cervical Ripening Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Prostaglandins |
| 10.1.2.Oxytocin |
| 10.1.3.Progesterone Receptor Antagonists |
| 10.1.4.Relaxin |
| 10.1.5.Estrogen |
| 10.1.6.Others |
| 10.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Intravenous |
| 10.2.3.Vaginal |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Cervical Ripening Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Prostaglandins |
| 11.1.2.Oxytocin |
| 11.1.3.Progesterone Receptor Antagonists |
| 11.1.4.Relaxin |
| 11.1.5.Estrogen |
| 11.1.6.Others |
| 11.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Intravenous |
| 11.2.3.Vaginal |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Cervical Ripening Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Prostaglandins |
| 12.1.2.Oxytocin |
| 12.1.3.Progesterone Receptor Antagonists |
| 12.1.4.Relaxin |
| 12.1.5.Estrogen |
| 12.1.6.Others |
| 12.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Intravenous |
| 12.2.3.Vaginal |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Cervical Ripening Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Prostaglandins |
| 13.1.2.Oxytocin |
| 13.1.3.Progesterone Receptor Antagonists |
| 13.1.4.Relaxin |
| 13.1.5.Estrogen |
| 13.1.6.Others |
| 13.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Intravenous |
| 13.2.3.Vaginal |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Ferring B.V (Switzerland) |
| 14.2.2.Azanta A/S (Denmark) |
| 14.2.3.Novartis AG (Switzerland) |
| 14.2.4.GlaxoSmithKline plc (U.K) |
| 14.2.5.AstraZeneca plc (U.K) |
| 14.2.6.Pfizer, Inc (U.S) |
| 14.2.7.Bayer AG (Germany) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.